Inventor
JIRONG PENG
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
A61KPreparations for medical, dental or toiletry purposes26%
C07DHeterocyclic compounds26%
C07BGeneral methods of organic chemistry13%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
PatentTitleYear
12,595,246Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof202612,390,464Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors202512,258,365Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof202512,187,707Pharmaceutical formulations of 202511,414,401Substituted 2-anilinopyrimidine derivatives as EGFR modulators202211,352,3412H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof202211,180,478Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to BETA PHARMA INC (7)· patent assignee history
2021–2026Based in US· patent location history
2022Patents assigned to BETA PHARMA SHANGHAI CO LTD (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BETA PHARMA INC | 7 | 2021–2026 |
| BETA PHARMA SHANGHAI CO LTD | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2021–2026 |